Table 1:

|  |  |  |
| --- | --- | --- |
| Trial | Interventions | Inclusion criteria |
| NORAM (N=95) | Induction therapy with methotrexate (MTX) or Cyclophosphamide (CYC) | Early systemic AAV (creatinine < 150μmol/L) |
| CYCAZAREM (N=155) | Remission maintenance therapy with azathioprine (AZA) or CYC | Generalised AAV  (creatinine < 500μmol/L) |
| CYCLOPS (N=148) | Induction therapy with intravenous (IV) pulsed CYC or oral CYC | Generalised AAV  Creatinine > 150μmol/L &  < 500μmol/L |
| MEPEX (N=137) | CYC induction therapy combined with plasma exchange or IV methylprednisolone | Severe AAV  Creatinine > 500μmol/L |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 2:** shows the baseline characteristics and long term outcome data | | | | | |
|  | NORAM (n=59) | CYCLOPS  (n=95) | CYCAZAREM  (n=118) | MEPEX  (n=82) | Total  (n=354) |
| Age in years | 52.5(40.8-62.4) | 60.7(48.5-68.5) | 57.3(46.2-67.7) | 66.5(57.9-71) | 60.7(48.2-69.1) |
| MPA | 5.1% | 47.4% | 37.3% | 63.4% | 40.7% |
| GPA | 94.9% | 40% | 62.7% | 36.6% | 55.9% |
| MPO | 13.6% | 52.6% | 24.6% | 41.5% | 34.4% |
| PR3 | 83.1% | 45.3% | 59.3% | 50% | 57.7% |
| BVAS^ at entry | 12(9-19) | 21(15-27) | 18(10-25) | 20(15-25) | 18(13-24) |
| BVAS^ at 3 months | 0(0-2) | 0(0-0) | 0(0-0) | 0(0-0) | 0(0-0) |
| BVAS ^ at 6 months | 0(0-0) | 0(0-0) | 0(0-0) | 0(0-0) | 0(0-0) |
| Proportion in remission at 3M | 61% | 83.1% | 95.8% | 92.7% | 85% |
| Proportion in remission at 6M | 78% | 84.7% | 97.9% | 96.3% | 89.8% |
| VDI^ at 3M | 0(0-1) | 0(0-1) | 0(0-0) | 0(0-1) | 0(0-1) |
| VDI^ at 6M | 1(0-2) | 1(0-3) | 2(1-3) | 3(2-3) | 2(1-3) |
| Mortality at a median f/u 5 years | 13.6% | 10.5% | 15.3% | 36.6% | 18.6% |
| ESRF at 5 years | 1.7% | 5.3% | 8.5% | 36.6% | 13% |
| eGFR^\* at entry | 79.7(71.7-98.3) | 32.2(19.5-53.7) | 31.4(19.7-63.7) | 6.7(4.5-8.4) | 27.8(10.3-64.7) |
| eGFR^ at 6M | 77.9(64.8-88.5) | 46.3(31.7-63.7) | 55.1(40.2-72.3) | 21.5(5.8-32.1) | 46.9(29.4-66.9) |
| Median follow-up in years | 6.0(3.2-7.3) | 4.5(3.5-5.5) | 8.5(4.9-9.3) | 5.1(1.0-7.3) | 5.7(3.32-8.33) |
| Years of enrolment | 1995-2000 | 1998-2002 | 1995-1997 | 1995-2001 | 1995-2002 |

^ Expressed as median with interquartile range within brackets

\*eGFR expressed as ml/min/1.73m²

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 3:** Cox proportional hazards regression and competing risk analyses | | | | | | | | |
|  | Cox proportional hazards model for mortality  N=329, events=62 | | Cox proportional hazards model for ESRF  N=290, events=35  (Late remission group excluded) | | Competing risk modelling for ESRF  N=290, events=35  competing events=34  (Late remission group excluded) | | Cox proportional hazards model for composite end-point of death or ESRF  N=321, events=75 | |
| Covariates | Hazard ratio | p-value | Hazard ratio | p-value | Sub-hazard ratio | p-value | Hazard ratio | p-value |
| Age in years | 1.09(1.05-1.13) | <0.001\* | 0.98(0.95-1) | 0.141 | 0.98(0.95-1) | 0.17 | 1.02(1-1.05) | 0.012\* |
| ANCA(PR3) | 0.83(0.42-1.63) | 0.601 | 0.74(0.33-1.64) | 0.461 | 1.01(0.49-2.07) | 0.96 | 0.89(0.5-1.56) | 0.69 |
| ANCA(Neg) | 1.3(0.46-3.72) | 0.614 | 0.32(0.05-2.13) | 0.243 | 0.42(0.1-1.71) | 0.23 | 1.02(0.39-2.67) | 0.96 |
| GPA | 0.4(0.19-0.8) | 0.011\* | 0.58(0.23-1.46) | 0.253 | 0.72(0.32-1.59) | 0.42 | 0.48(0.26-0.89) | 0.019\* |
| BVAS at entry (per unit rise) | 1.03(1-1.07) | 0.036\* | 1.04(0.98-1.1) | 0.175 | 1.02(0.96-1.07) | 0.44 | 1.03(1-1.07) | 0.03\* |
| eGFR at 6M (per ml/min increase) | 0.96(0.94-0.98) | <0.001\* | 0.9(0.87-0.93) | <0.001\* | 0.9(0.88-0.92) | <0.001\* | 0.94(0.92-0.95) | <0.001\* |
| Male | 2.17(1.18-3.99) | 0.012\* | 2.84(1.12-7.21) | 0.027\* | 2.36(0.93-5.95) | 0.068 | 2.02(1.17-3.47) | 0.011\* |
| VDI > 2 at 6M | 1.34(0.74-2.44) | 0.326 | 1.7(0.8-3.6) | 0.165 | 1.63(0.76-3.49) | 0.2 | 1.33(0.81-2.2) | 0.256 |
| Late remission | 3.31(1.28-8.57) | 0.013\* | - | - | - | - | 2.94(1.1-7.85) | 0.031\* |
| Relapsing disease | 6.59(2.18-19.87) | 0.001\* | 34.22(4.72-247.8) | <0.001\* | 15.75(2.53-97.92) | 0.003\* | 8.21(2.73-24.65) | <0.001\* |
| Refractory disease | 6.15(2.26-16.73) | <0.001\* | 9.64(2.25-41.29) | 0.002\* | 5.98(1.32-26.97) | 0.02\* | 4.89(1.96-12.18) | 0.001\* |
| Cycazarem | 0.11(0.03-0.39) | 0.001\* | 0.19(0.01-2.71) | 0.221 | 0.19(0.01-3.25) | 0.25 | 0.15(0.04-0.49) | 0.002\* |
| Cyclops | 0.13(0.04-0.45) | 0.001\* | 0.52(0.04-5.9) | 0.603 | 0.29(0.02-3.31) | 0.32 | 0.26(0.09-0.77) | 0.015\* |
| Mepex | 0.11(0.03-0.41) | 0.001\* | 0.2(0.01-2.77) | 0.23 | 0.27(0.01-5.58) | 0.4 | 0.15(0.04-0.51) | 0.002\* |
| Year | 1.01(0.83-1.24) | 0.858 | 1.46(1.14-1.88) | 0.003\* |  |  | 1.17(0.98-1.39) | 0.079 |

^ Reference group for ANCA: MPO; $ Reference group for disease status: complete remission #Reference group for trial: NORAM